Is Pfizer Poised to Head Higher?

With shares of Pfizer (NYSE:PFE) trading around $29, is PFE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Pfizer is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company manages its operations through five segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health and Consumer Healthcare, and Nutrition. Pfizer’s main products are human and animal biologic and small molecule medicines, as well as vaccines, nutritional products, consumer healthcare products, and products for the prevention and treatment of diseases in livestock and companion animals.

In its bid for AstraZeneca, Pfizer is finding out that some merger offers need to be sweet enough for everyone. On Sunday, Pfizer made what it called its “final” $119 billion offer for AstraZeneca, which is based in London. Pfizer also stated that while it wanted a deal, it was only making a soft “nonbinding” offer at this time. Pfizer said it would not start a full-fledged hostile offer for AstraZeneca. A hostile bid would have involved offering terms that AstraZeneca’s shareholders could accept without the approval of AstraZeneca’s board. Given the price Pfizer offered, such a maneuver had a real chance of success. But Pfizer did not go that route, instead leaving the fate of its offer in the hands of AstraZeneca’s board of directors.